DIDREX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIDREX (DIDREX).
Sympathomimetic amine with anorectic activity; releases norepinephrine and dopamine from nerve terminals in the hypothalamus, suppressing appetite.
| Metabolism | Hepatic metabolism via CYP2D6 and CYP3A4; active metabolite benzphetamine. |
| Excretion | Renal excretion of metabolites and unchanged drug (approximately 80% as unchanged benzphetamine and its metabolites within 96 hours); biliary/fecal excretion accounts for less than 10%. |
| Half-life | Terminal elimination half-life of approximately 16-31 hours after a single oral dose; with repeated dosing, half-life may be prolonged due to accumulation. |
| Protein binding | Approximately 75-85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution not well-established in humans; estimated to be 3-5 L/kg based on animal data, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability not specifically reported for benzphetamine; typical sympathomimetic amines have oral bioavailability of 20-40% due to first-pass metabolism; absorption is rapid and complete. |
| Onset of Action | Oral: clinical anorectic effect occurs within 1-3 hours after administration. |
| Duration of Action | Oral: Anorectic effect persists for approximately 4-6 hours; duration of appetite suppression may be shorter with chronic use due to tolerance. |
25 mg orally three times daily, 1 hour before meals.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min). No specific adjustment for mild to moderate impairment, but use with caution. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in Child-Pugh class B; reduce dose by 50%. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-17, 25 mg once daily, titrate based on response. |
| Geriatric use | Start at 12.5 mg once daily; increase cautiously. Monitor for cardiovascular and psychiatric effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIDREX (DIDREX).
| Breastfeeding | Contraindicated during breastfeeding. DIDREX is excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants, including irritability, feeding difficulties, and growth suppression. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of fetal malformations, particularly neural tube defects and cardiovascular anomalies. Second and third trimesters: increased risk of neonatal withdrawal, intrauterine growth restriction, and premature birth. Avoid in pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity, advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, concomitant MAOIs or within 14 days.
| Precautions | Abuse potential (Schedule III), cardiovascular risks (hypertension, arrhythmias), pulmonary hypertension, psychiatric adverse effects, tolerance development, use with MAOIs contraindicated. |
Loading safety data…
| Fetal Monitoring |
| Not applicable as drug is contraindicated. If inadvertent exposure occurs, monitor fetal growth via ultrasound, assess for congenital anomalies, and conduct neonatal observation for withdrawal symptoms. |
| Fertility Effects | May impair female fertility due to hormonal disruption; oligomenorrhea or amenorrhea reported. Reversible upon discontinuation. Male fertility may be affected; spermatogenesis impairment possible. |